NOVO.B.DK

435.9

+0.91%↑

GMAB.DK

1,305.5

-1.21%↓

HLUNB.DK

35.62

-0.22%↓

ZEAL.DK

357.5

+1.22%↑

AMBUB.DK

100.4

+0.6%↑

NOVO.B.DK

435.9

+0.91%↑

GMAB.DK

1,305.5

-1.21%↓

HLUNB.DK

35.62

-0.22%↓

ZEAL.DK

357.5

+1.22%↑

AMBUB.DK

100.4

+0.6%↑

NOVO.B.DK

435.9

+0.91%↑

GMAB.DK

1,305.5

-1.21%↓

HLUNB.DK

35.62

-0.22%↓

ZEAL.DK

357.5

+1.22%↑

AMBUB.DK

100.4

+0.6%↑

NOVO.B.DK

435.9

+0.91%↑

GMAB.DK

1,305.5

-1.21%↓

HLUNB.DK

35.62

-0.22%↓

ZEAL.DK

357.5

+1.22%↑

AMBUB.DK

100.4

+0.6%↑

NOVO.B.DK

435.9

+0.91%↑

GMAB.DK

1,305.5

-1.21%↓

HLUNB.DK

35.62

-0.22%↓

ZEAL.DK

357.5

+1.22%↑

AMBUB.DK

100.4

+0.6%↑

Search

Coloplast A-S (Class B)

Chiusa

602 -0.23

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

595

Massimo

610

Metriche Chiave

By Trading Economics

Entrata

-132M

912M

Vendite

-96M

6.9B

P/E

Media del settore

30.208

50.291

EPS

4.34

Rendimento da dividendi

3.61

Margine di Profitto

13.16

Dipendenti

16,741

EBITDA

-42M

2.2B

Raccomandazioni

By TipRanks

Raccomandazioni

Neutrale

Previsioni per 12 mesi

+11.86% upside

Dividendi

By Dow Jones

Rendimento da dividendi

Media del settore

3.61%

2.40%

Utili prossimi

19 ago 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

-19B

138B

Apertura precedente

602.23

Chiusura precedente

602

Coloplast A-S (Class B) Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

26 giu 2025, 23:49 UTC

Utili

Nike Sees Sales Decline Decelerating in 1Q as Turnaround Strategy Plays Out -- 2nd Update

26 giu 2025, 22:19 UTC

Acquisizioni, Fusioni, Takeovers

FTC Clears Alimentation Couche-Tard's $1.57 Billion GetGo Acquisition

26 giu 2025, 21:30 UTC

Utili

Nike 4Q Profit, Revenue Slides as Turnaround Strategy Plays Out -- Update

26 giu 2025, 21:07 UTC

Utili

Nike 4Q Profit, Revenue Slide as Turnaround Strategy Plays Out

26 giu 2025, 23:49 UTC

Discorsi di Mercato

Nikkei May Rise as Fears About Middle East Conflict Ebb -- Market Talk

26 giu 2025, 23:39 UTC

Discorsi di Mercato

Gold Edges Lower, Weighed by Stronger-Than-Expected U.S. Data -- Market Talk

26 giu 2025, 23:34 UTC

Acquisizioni, Fusioni, Takeovers

Wesfarmers: Lease Reset Provides Opportunity for Upgrades, Extensions

26 giu 2025, 23:33 UTC

Acquisizioni, Fusioni, Takeovers

Wesfarmers: 62 BWP-Owned Bunnings Sites Get Significantly Longer Leases

26 giu 2025, 23:32 UTC

Acquisizioni, Fusioni, Takeovers

Wesfarmers Will No Longer Receive Earnings From BWP Management

26 giu 2025, 23:32 UTC

Acquisizioni, Fusioni, Takeovers

Wesfarmers to Increase BWP Holding to 23.5% From 22.3%

26 giu 2025, 23:31 UTC

Acquisizioni, Fusioni, Takeovers

Wesfarmers: New BWP Units Priced at 9.2% Premium to Last Close

26 giu 2025, 23:31 UTC

Acquisizioni, Fusioni, Takeovers

BWP to Pay A$100 Mln Cash, A$42.6 Mln in New Units

26 giu 2025, 23:30 UTC

Acquisizioni, Fusioni, Takeovers

Wesfarmers' Bunnings, BWP Trust to Extend and Vary Leases

26 giu 2025, 23:29 UTC

Acquisizioni, Fusioni, Takeovers

Wesfarmers to Sell BWP Management to BWP Trust for A$142.6M

26 giu 2025, 23:19 UTC

Acquisizioni, Fusioni, Takeovers

Andlauer Healthcare Group: Ontario Superior Court of Justice Issues Final Order Approving Sale to UPS

26 giu 2025, 22:06 UTC

Utili

Nike's Earnings Were Ugly. But They're Better Than Feared. -- Barrons.com

26 giu 2025, 21:15 UTC

Utili

Nike 4Q Profit, Rev Slides as Turnaround Strategy Plays Out -- Update

26 giu 2025, 21:07 UTC

Acquisizioni, Fusioni, Takeovers

Couche-Tard: 35 Stores to Be Divested in Accordance With Regulatory Requirements >ATD.T

26 giu 2025, 21:07 UTC

Acquisizioni, Fusioni, Takeovers

Couche-Tard: GetGo Will Operate as Separate, Stand-Alone Business Unit, Maintain myPerks Loyalty Program >ATD.T

26 giu 2025, 21:07 UTC

Acquisizioni, Fusioni, Takeovers

Couche-Tard: Buyer Will be Approved by the FTC >ATD.T

26 giu 2025, 21:07 UTC

Utili

Nike's Earnings Were Ugly. But They're Better Than Feared. -- Barrons.com

26 giu 2025, 21:06 UTC

Acquisizioni, Fusioni, Takeovers

Couche-Tard Agreed to Sell 35 Sites, Including 34 Circle K Locations and One GetGo Property >ATD.T

26 giu 2025, 21:06 UTC

Acquisizioni, Fusioni, Takeovers

Couche-Tard: Transaction Is Expected to Close in the Coming Days >ATD.T

26 giu 2025, 21:06 UTC

Discorsi di Mercato

Bank of Mexico Seen Likely to Slow Pace of Rate Cuts -- Market Talk

26 giu 2025, 21:05 UTC

Acquisizioni, Fusioni, Takeovers

COUCHE-TARD RECEIVES FTC CLEARANCE TO COMPLETE ACQUISITION OF GETGO CAFÉ + MARKET >ATD.T

26 giu 2025, 21:05 UTC

Acquisizioni, Fusioni, Takeovers

COUCHE-TARD RECEIVES FTC CLEARANCE TO COMPLETE ACQUISITION OF GETGO CAFÉ + MARKET >ATD.T

26 giu 2025, 20:52 UTC

Utili

Nike 4Q Profit, Rev Slide as Turnaround Strategy Plays Out

26 giu 2025, 20:51 UTC

Utili

Correct: Nike 4Q Net $211M, Not $200M >NKE

26 giu 2025, 20:50 UTC

Discorsi di Mercato

Tech, Media & Telecom Roundup: Market Talk

26 giu 2025, 20:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

Confronto tra pari

Modifica del prezzo

Coloplast A-S (Class B) Previsione

Obiettivo di Prezzo

By TipRanks

11.86% in crescita

Previsioni per 12 mesi

Media 901.38 DKK  11.86%

Alto 1,056 DKK

Basso 720 DKK

Basato su 8 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Coloplast A-S (Class B) - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Neutrale

8 ratings

2

Acquista

4

Mantieni

2

Vendi

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Coloplast A-S (Class B)

Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Continence Care, Voice and Respiratory Care, Interventional Urology, and Advanced Wound Care segments. It provides ostomy care products, including SenSura Mio, which provides fit individual body shapes and optimal discretion for various types of ostomies; and SenSura Ostomy care solutions, as well as ostomy accessories under the Brava brand. The company also offers continence care products, such as Conveen Active urine bags; SpeediCath catheters that offer catheterization for both genders; and Peristeen Plus, a transanal irrigation system. In addition, it provides wound care products comprising conforming dressing under the Biatain Silicone brand and hydrocolloid dressing under the Comfeel brand; and skin care products that include cleansers, moisturizers, skin protectants, antifungal products, and hand cleansers, as well as InterDry, a skin fold management solution. Further, the company develops, produces, and markets products for the surgical treatment of urological and gynecological disorders, such as urinary stone diseases, benign prostate hyperplasia, voiding dysfunctions, erectile dysfunction, and urinary incontinence. Additionally, its voice and respiratory care solutions include laryngectomy care products comprising Provox, a voice prosthesis for speaking, HMEs, adhesives, laryngectomy tubes for breathing, devices for speaking hands-free, and accessories, as well as tracheostomy care products under Tracoe brand. Coloplast A/S was founded in 1954 and is headquartered in Humlebæk, Denmark.